Skip to main content
Sign In
 

Institutional Biosafety Committee

Office of Research Committee Support


E-mail: IBC@ucdenver.edu

The CU Denver Institutional Biosafety Committee provides review and approval for a wide range of research activities on CU campuses. Protocols are reviewed and overseen for compliance with the National Institute of Health (NIH) Guidelines and Federal Select Agents Regulations, as well as state & institutional requirements for research on campus.

The IBC meetings monthly to review biosafety applications. 2018 & 2019 meeting dates & submission deadlines are linked below. Please refer to the website for all meeting dates & submission deadlines.


Responsibilities of the IBC

Review and approval of research on campus involving any of the items indicated below, alone or in combination:

  • Recombinant DNA materials (including recombinant proteins, vectors, etc)
  • Transgenic animals or plants
  • Infectious materials
  • Biohazardous materials
  • Select Agent toxins
  • Human materials (cells, fluids, tissues, etc)
  • Human Gene Transfer or Live Vaccine clinical trials
  • Clinical trials involving institutionally created investigational compounds
  • Incident Reporting and Investigations for incidents involving infectious or recombinant DNA materials

Biosafety Authorization F​orms

All new and renewal IBC applications must be entered in the eSirius system- word files will not be accepted. For amendment instructions, please contact the IBC Coordinator (ibc@ucdenver.edu) for instructions.

  • The new eSirius system can be accessed here. Before attempting to submit an IBC protocol, please review this document​ regarding the process of accessing & starting a new protocol in eSirius- IBC eSirius- accessing system & starting IBC
  • Please review the CU Denver IBC Compliance Note
  • If working with Select Agent Toxins, the Appendix A and Appendix A SOP must be completed & attached to your eSirius application
  • If working with transgenic animals in any capacity, or if exposing non-transgenic animals to IBC covered agents, the Appendix T​ must be completed & attached to your eSirius application

Human Clinical Trial Application Information

The IBC reviews human clinical trials involving Human Gene Transfer, Live Vaccine, or some institutionally-created investigational compounds. Clinical trials ARE NOT processed in eSirius at this time. Please contact the IBC Coordinator for correct forms and information regarding IBC review of clinical trials.


NIH References

​​​​​​​​​​​​​​​​